Levels and trends of persistent organic pollutants in human populations living in the Arctic.


Journal

International journal of circumpolar health
ISSN: 2242-3982
Titre abrégé: Int J Circumpolar Health
Pays: United States
ID NLM: 9713056

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: ppublish

Résumé

The Arctic Monitoring Assessment Program (AMAP) is tasked with monitoring and assessing the status of environmental contaminants in the Arctic, documenting levels and trends, and producing science-based assessments. The objectives of this paper are to present the current levels of persistent organic pollutants (POPs) across the Arctic, and to identify trends and knowledge gaps as detailed in the most recent AMAP Human Health Assessment Report. Many Arctic populations continue to have elevated levels of these contaminants, and the highest levels of POPs were observed in populations from Greenland, Faroe Islands, and Nunavik (Canada), as well as populations in the coastal Chukotka district (Russia) for legacy POPs only. Concentrations of most POPs are declining in Arctic populations in regions where time trends data exist, although the declines are not consistent across all regions. The exceptions are per- and polyfluoroalkyl substances, with concentrations of some long-chain PFAS such as perfluorononanoic acid increasing in populations in Nunavik, Greenland and Sweden. This paper provides a more extensive summary of levels of contaminants in adults, pregnant women, and children across the Arctic than previous AMAP human health assessments, particularly for levels of long-chain PFAS, which are currently under consideration for inclusion in the Stockholm Convention.

Identifiants

pubmed: 39288300
doi: 10.1080/22423982.2024.2392405
doi:

Substances chimiques

Persistent Organic Pollutants 0
Environmental Pollutants 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2392405

Auteurs

Bryan Adlard (B)

Environmental Health Science and Research Bureau, Health Canada, Ottawa, Canada.

Eva C Bonefeld-Jørgensen (EC)

Centre for Arctic Health & Molecular Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
Greenland Center for Health Research, University of Greenland, Nuussuaq, Greenland.

Alexey A Dudarev (AA)

Arctic Environmental Health Department, Northwest Public Health Research Center, St-Petersburg, Russia.

Kristin Olafsdottir (K)

Department of Pharmacology & Toxicology, University of Iceland, Reykjavik, Iceland.

Khaled Abass (K)

Department of Environmental Health Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Research Institute of Science and Engineering, University of Sharjah, Sharjah, United Arab Emirates.
Research Unit of Biomedicine and Internal Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland.

Maria Averina (M)

Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.

Pierre Ayotte (P)

Centre de recherche du CHU de Québec-Université Laval and INSPQ, Québec City, Québec, Canada.

James Berner (J)

Department of Environment and Health, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.

Sam Byrne (S)

Department of Biology and Program in Global Health, Middlebury College, Middlebury, USA.

Élyse Caron-Beaudoin (É)

Department of Health and Society, University of Toronto Scarborough, Ontario, Canada.

Mallory Drysdale (M)

School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.

Pierre Dumas (P)

Centre de recherche du CHU de Québec-Université Laval and INSPQ, Québec City, Québec, Canada.

Joshua Garcia-Barrios (J)

School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.

Irina Gyllenhammar (I)

Swedish Food Agency, Department of Risk & Benefit Assessment, Uppsala, Sweden.

Brian Laird (B)

School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.

Melanie Lemire (M)

Centre de recherche du CHU de Québec-Université Laval, Québec City, Québec, Canada.
Département de médecine sociale et préventive, Institut de biologie intégrative et des systèmes, Université Laval, Québec City, Québec, Canada.

Amira Aker (A)

Centre de recherche du CHU de Québec-Université Laval, Québec City, Québec, Canada.

Sanna Lignell (S)

Swedish Food Agency, Department of Risk & Benefit Assessment, Uppsala, Sweden.

Manhai Long (M)

Centre for Arctic Health & Molecular Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.

Karin Norström (K)

Swedish Environmental Protection Agency, Stockholm, Sweden.

Sara Packull-McCormick (S)

School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.

Maria Skaalum Petersen (MS)

Department of Research, National Hospital of the Faroe Islands, Torshavn, Faroe Islands.

Mylene Ratelle (M)

School of Public Health, University of Montreal, Montreal, Quebec, Canada.

Arja Rautio (A)

Biomedicine and Internal Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland.

Amalie Timmerman (A)

National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.

Gunnar Toft (G)

Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.

Pal Weihe (P)

Department of Research, National Hospital of the Faroe Islands, Torshavn, Faroe Islands.

Therese Haugdahl Nøst (TH)

Department of Community Medicine, UiT, The Arctic University of Norway, Tromsø, Norway.
HUNT Research Centre, Norwegian University of Science and Technology, Tromsø, Norway.
Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.
HUNT Centre for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Tromsø, Norway.

Maria Wennberg (M)

Section of Sustainable Health, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH